Gold Prices Steady Ahead of U.S. Inflation Data and Fed Decision 
Asian Stocks Mixed as AI Chip Rally Meets Oil Surge 
UK Food Inflation Forecast to Hit 6.4% by Mid-2027 
Asian Stocks Fall as Oil Tops $100, Yields Rise 
Hormuz Shipping Slows as Iran Threats Lift Oil Risks 
Fitch Eyes Japan Budget for Fiscal Discipline 
US Stock Futures Mixed as Fed Rate Hike Bets Rise 
South Korea GDP Surges on Chip and AI Boom 
China Buys 1 Million Tons of U.S. Soybeans Ahead of Xi Visit 
Iran Threatens Gulf Energy Assets as U.S. Tensions Escalate 
Gold Prices Rise as Yen Rally Weakens Dollar 
U.S. Stock Futures Steady as Oil Tops $100 Ahead of Inflation Data 
Gold Prices Rebound as Dollar Weakens, Fed Decision Looms 
China Inflation Accelerates in August as CPI, PPI Rise 
ECB Rate Hike in Focus as Oil Tops $100 
Asian Currencies Steady as Yen Holds Firm, Oil Tops $100 
German Inflation Accelerates to 2.9% in August 
Add as a preferred source on Google
Roche CEO Urges FTC to Block Novo Nordisk's Acquisition of Catalent
Roche's CEO, Thomas Schinecker, has called on authorities to prevent Novo Nordisk’s controlling shareholder, Novo Holdings, from acquiring contract drug manufacturer Catalent. Schinecker voiced concerns about the potential negative impact on competition, particularly for smaller industry players. "While this doesn’t directly affect us, it could restrict options for smaller competitors if the number of available contract manufacturers decreases," he stated during a media call following Roche's quarterly sales report.
Consumer advocacy groups and labor unions recently petitioned the U.S. Federal Trade Commission (FTC) to intervene against the acquisition, citing risks to competition in the market for weight loss drugs and advanced gene therapies. They argued that the deal could limit opportunities for rivals like Amgen, Pfizer, Roche, and AstraZeneca, all of whom are developing obesity treatments, some based on complex peptides.
Other companies, such as Viking Therapeutics, Structure Therapeutics, and Sun Pharma, could also be impacted by this acquisition.
In contrast, Novo Holdings has defended its position, asserting a "pro-competitive rationale" for the deal. Teresa Graham, head of Roche's pharmaceutical division, reassured stakeholders that Roche is well-prepared, stating, "We have secured capacity with other contract manufacturing organizations and are confident in our production capabilities."
Roche plans to utilize a combination of in-house and external manufacturing for its forthcoming obesity drug launches, ensuring a steady supply chain.
